Lancôme x Timeline: First Mitochondria-Targeting Skincare Reveal at AAD 2026
SKIN

Lancôme x Timeline: First Mitochondria-Targeting Skincare Reveal at AAD 2026

By Suji · · https://www.premiumbeautynews.com/en/lancome-and-timeline-unveil-first,24117
KO | EN

Lancôme partnered with Timeline to unveil their first mitochondria-targeting skincare collaboration at the American Academy of Dermatology (AAD) annual meeting, March 27-29, 2026. Timeline is a Swiss biotech backed by Nestlé Health Science, with 15+ years of research on Urolithin A (branded as Mitopure).

Urolithin A, a mitochondria-targeting postbiotic

Urolithin A is a compound produced when ellagitannins, found in pomegranate and berries, are metabolized by gut microbiota. Timeline defines it as a “mitochondria-targeting postbiotic.” The core mechanism is mitophagy, the cellular process of clearing damaged mitochondria and replacing them with new ones.

Mitochondria are the cell’s energy factories. As they decline with age, skin cell vitality drops. Activating mitophagy is a new target for cellular renewal. Timeline already markets an oral supplement (Mitopure) and now expands into topical skincare with Lancôme.

EUR 50M R&D, 15 years, 50+ patents

The scale of this partnership is notable. EUR 50M in R&D investment, 15+ years of research, more than 50 patents. A signal that luxury skincare is bringing life-science IP directly to the counter, not just marketing claims.

Lancôme launched Absolue Longevity Soft Cream and Cell BioPrint diagnostics in 2025. The Mitopure collaboration extends that line. Diagnostics (Cell BioPrint measuring aging markers) and treatment (Mitopure activating mitophagy) connect within a single product family.

Mitophagy as the new luxury skincare standard

The mechanism unit for skin aging is shifting. From collagen stimulation and antioxidants toward mitochondrial function recovery and cellular autophagy. The mechanism is moving deeper inside the cell.

What changes for the consumer. Marketing language shifts from “wrinkle improvement” to “cellular energy recovery.” A new standard for luxury skincare backed by clinical mechanism evidence.

Combined with the NMN, NR, NAD+ booster supplement trends announced the same quarter, the picture sharpens. Mitochondrial and NAD+ mechanisms are integrating across topical and oral boundaries into a single matrix.

Connection to the Nestlé lineup

Timeline’s parent company is Nestlé Health Science. The same quarter, Nestlé presented NAD+ microbiome mechanism data at in-cosmetics 2026. Within the same group, mitochondrial (Timeline) and NAD+ (Nestlé) mechanisms are forming a category in parallel.

Lancôme x Timeline is the luxury channel. Mitopure supplements are the medical/wellness channel. Nestlé NAD+ is the food and beverage layer. A single mechanism diversifying across channels into an integrated matrix.

Korean market entry

The Korean launch timing for the Lancôme x Timeline line is undecided. Likely 6-12 months after Lancôme’s global rollout. Mitopure oral supplements are already sold in select global markets; Korean availability is possible in 2026-2027.

The message to consumers. Luxury skincare is no longer differentiating on marketing but on mechanism. Mitochondria, mitophagy, and cellular energy will be the most-spoken words at cosmetics counters next quarter.